Related Experiment Video

Updated: Oct 8, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K

Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment

Tomoya Wadayama1, Mikito Shimizu2, Tomohiro Yata1

  • 1Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Journal of Neuroimmunology
|January 1, 2022
PubMed

Insights

This case report explores anti-interleukin-6 (IL-6) therapy for cryptogenic new-onset refractory status epilepticus (C-NORSE). Tocilizumab, an IL-6 blocker, stopped seizures but had a poor overall outcome.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Cryptogenic new-onset refractory status epilepticus (C-NORSE) is a severe neurological condition.
  • While immune-mediated causes are suspected, many C-NORSE cases are refractory to standard immunotherapy.

Purpose of the Study:

  • To investigate the efficacy of anti-interleukin-6 (IL-6) therapy in a patient with C-NORSE.
  • To describe a case of C-NORSE treated with tocilizumab, an IL-6 receptor antagonist.

Main Methods:

  • Case report of a 46-year-old woman diagnosed with C-NORSE.
  • Administration of tocilizumab, a monoclonal antibody targeting the IL-6 receptor.

Main Results:

  • Tocilizumab administration led to the cessation of prolonged status epilepticus.
  • Despite seizure control, the patient experienced a poor final outcome.

Conclusions:

  • Anti-IL-6 therapy, specifically with tocilizumab, shows potential for seizure cessation in select C-NORSE cases.
  • Further research is warranted to evaluate the broader efficacy and safety of IL-6 blockade in C-NORSE.
Abstract

Keywords:
Anti-IL-6 treatmentNew-onset refractory status epilepticusStatus epilepticusTocilizumab

More Related Videos

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.6K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

9.7K

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
350
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
335
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
579
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
777
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
252
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
510